Back to results
US 11,530,258 B2Granted
Use of SRSF3 agents for the treatment and/or prevention of neurological conditions, cancer, bacterial infections or viral infections
AssigneeUniversite Laval
InventorsJasna Kriz, Hejer Boutej
Life of this patent
Estimating the term…
Abstract
The present description relates to the use of a SRSF3 agent for regulating the function of a myeloid cell, such as a microglial cell and/or monocyte, for treating neurological conditions, cancers, bacterial infections and viral infections wherein the SRSF3 agent inhibits expression or function of SRSF3.
Claims15
A method for:
- the treatment of a neurological condition which is vascular dementia, frontotemporal lobar degeneration (FTD), Alzheimer, Amyotrophic Lateral Sclerosis (ALS), Progressive bulbar palsy (PBP), Primary lateral sclerosis (PLS), Kennedy's Disease or Parkinson's disease;
- the method comprising administering an effective amount of at least one SRSF3 agent which is an antibody or an antisense/iRNA to a human patient in need thereof, wherein the SRSF3 agent inhibits expression or function of SRSF3.
Dependencies are inferred from the claim text.